symmetric dimethylarginine has been researched along with Left Ventricular Hypertrophy in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Atzler, D; Böger, RH; Chen, P; Chen, Y; Fassett, J; Guo, H; Hu, X; Kwak, D; Liu, X; Lu, Z; Schwedhelm, E; Wang, H; Xu, X; Yue, W; Zhang, P | 1 |
1 other study(ies) available for symmetric dimethylarginine and Left Ventricular Hypertrophy
Article | Year |
---|---|
Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
Topics: Amidohydrolases; Animals; Arginine; Atrial Natriuretic Factor; Disease Models, Animal; Fibrosis; Genetic Predisposition to Disease; Hypertrophy, Left Ventricular; Male; Mice, Knockout; Myocytes, Cardiac; Nitric Oxide; Phenotype; Signal Transduction; Tyrosine; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2017 |